Monepantel trial achieves successful anti-cancer outcome - Recruitment on hold during interim analysis and report preparation.

Dr Richard Mollard - Full Interview Ticker TV - 17th June 2020

pharmaus 210


PAA is a clinical-stage company developing targeted cancer therapeutics to address both human and animal healthcare. The company specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported by PAA’s subsidiary, Epichem, which is a highly successful contract medicinal chemistry company that generates significant annual revenues.

Read more

pharmaust research


Monepantel is a potent small molecule drug that has been shown to modulate the mTOR pathway, which plays a pivotal role in driving many cancers.

Read more

pharmaust cancer research news